The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Laura Fancello 1,* , Kim R. Kampen 1,* , Isabel J.F. Hofman 1 , Jelle Verbeeck 1 and Kim De Keersmaecker 1 1 KU Leuven-University of Leuven, Department of Oncology, LKI-Leuven Cancer Institute, Leuven, Belgium * These authors have contributed equally to this work Correspondence to: Kim De Keersmaecker, email: // Keywords : ribosomal protein, haploinsufficient tumor suppressor, TCGA, breast cancer Received : January 05, 2017 Accepted : January 11, 2017 Published : January 29, 2017 Abstract For many years, defects in the ribosome have been associated to cancer. Recently, somatic mutations and deletions affecting ribosomal protein genes were identified in a few leukemias and solid tumor types. However, systematic analysis of all 81 known ribosomal protein genes across cancer types is lacking. We screened mutation and copy number data of respectively 4926 and 7322 samples from 16 cancer types and identified six altered genes ( RPL5 , RPL11 , RPL23A , RPS5 , RPS20 and RPSA ). RPL5 was located at a significant peak of heterozygous deletion or mutated in 11% of glioblastoma, 28% of melanoma and 34% of breast cancer samples. Moreover, patients with low RPL5 expression displayed worse overall survival in glioblastoma and in one breast cancer cohort. RPL5 knockdown in breast cancer cell lines enhanced G2/M cell cycle progression and accelerated tumor progression in a xenograft mouse model. Interestingly, our data suggest that the tumor suppressor role of RPL5 is not only mediated by its known function as TP53 or c-MYC regulator. In conclusion, RPL5 heterozygous inactivation occurs at high incidence (11-34%) in multiple tumor types, currently representing the most common somatic ribosomal protein defect in cancer, and we demonstrate a tumor suppressor role for RPL5 in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Vlachos, A., Rosenberg, P. S., Atsidaftos, E., Alter, B. P., & Lipton, J. M. (2012) · Blood · doi:10.1182/blood-2011-08-375972 · Cited by 309
MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits
Liu, H., Radisky, D. C., Yang, D., Xu, R., Radisky, E. S., Bissell, M. J., & Bishop, J. M. (2012) · Nature Cell Biology · doi:10.1038/ncb2491 · Cited by 181 · cited 1×
“c-MYC overexpression in MDA-MB-231 cells has previously been shown to increase tumor volumes in vivo [48] and may have contributed to faster tumor growth as compared to MCF7 tumors.”
Cited by
Ribosome biogenesis in cancer: new players and therapeutic avenues
Pelletier, J., Thomas, G., & Volarević, S. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.104 · Cited by 812
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 408
Drug resistance in multiple myeloma
Robak, P., Drozdz, I., Szemraj, J., & Robak, T. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.001 · Cited by 283
The Ribosome Biogenesis—Cancer Connection
Penzo, M., Montanaro, L., Treré, D., & Derenzini, M. (2019) · Cells · doi:10.3390/cells8010055 · Cited by 242
“Furthermore, recent studies on paediatric cases of T-ALL suggest a driver role for RPL5-uL18 and RPL10-uL16 mutations in the development of this disease [101] and the De Keersmaecker group proposed also a p53-independent (ribosome-dependent?) mechanism underlying RPL5-uL18 inactivation–mediated cancer commitment in br…”
BackgroundKampen, K. R., Sulima, S. O., Vereecke, S., & De Keersmaecker, K. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz637 · Cited by 214
“A tumor suppressor role for RPL5 is supported by the fact that its downregulation accelerates tumor formation in xenografted breast cancer cell lines (32).”
BackgroundSelf-citation
Metadata
- Authors
- Fancello, L., Kampen, K. R., Hofman, I. J. F., Verbeeck, J., & Keersmaecker, K. D.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-01-29
- Volume
- 8
- Issue
- 9
- Pages
- 14462-14478
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2583421453
- Cited by
- 122
- References
- 5
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.